Updated October 31, 2026 · Research & context
There’s a very unglamorous problem with psychedelic therapy: somebody has to book the room.
Long sessions don’t just ask patients to clear their calendars. They require trained staff, monitoring, space, and a way to pay for all of it. A promising treatment that’s too expensive or difficult to deliver can stay out of reach for the people who need it.
So when a study claims that a psychedelic experience may be over relatively quickly while the improvement in depression lasts for weeks, it deserves attention. It also deserves a closer read than the inevitable “two-hour trip cures depression” headlines.
On October 26, JAMA published a phase 2b trial of intranasal mebufotenin—the clinical name for 5-MeO-DMT—in people with treatment-resistant depression. The findings were encouraging. They weren’t quite the neat story a headline might suggest.
The treatment wasn’t a mushroom trip in a bottle
If you’ve read our earlier piece on 5-MeO-DMT and its “God Molecule” mythology, you know the compound comes with a considerable amount of cultural baggage. Stories of ego dissolution, transcendent encounters, and the Colorado River toad tend to drown out the less cinematic questions.
This study wasn’t testing a ceremony, a toad secretion, or a recreational dose. Researchers used a pharmaceutical nasal-spray formulation of mebufotenin benzoate, given by trained clinicians in a monitored setting, with psychological support before, during, and after treatment. The distinction matters. A drug tested under careful clinical conditions is not evidence that taking an unregulated substance on your own produces the same results—or carries the same risks.
Researchers enrolled adults whose major depression had not improved adequately after two to five antidepressant treatments in their current episode. The trial ran at 38 sites across the United States, Australia, and Europe. Of 196 participants randomized, 193 were included in the main analysis.
People were assigned to receive a single nasal dose of 8 milligrams, 12 milligrams, or a very small 0.3-milligram comparison dose. Those groups weren’t equal in size: 46 people received 8 mg, 73 received 12 mg, and 74 received the comparator. Researchers followed participants for eight weeks.
What actually improved?
The trial used the Montgomery–Åsberg Depression Rating Scale, a clinician-rated measure of depression severity. It’s a structured assessment, not a question about whether someone had a meaningful or profound experience.
Twenty-nine days after dosing, the people given 12 mg had improved by an average of 11.1 points from their starting score, compared with 5.5 points in the low-dose group. After adjusting for the study design, the difference between the groups was 5.3 points in favor of 12 mg. That met the trial’s prespecified primary statistical test.
Here’s where the story gets interesting. The 8-mg group also did better than the low-dose comparison, with an average 12.5-point drop from baseline and an adjusted between-group difference of 6.2 points at day 29. A stronger dose didn’t obviously mean a better outcome.
The response and remission figures tell a similar story. At day 29, roughly 35% of the 8-mg group and 34% of the 12-mg group met the study’s definition of response, compared with 12% of the comparison group. The remission proportions were 26%, 18%, and 8%, respectively. These are group-level results, not a prediction of what will happen to any particular person.
Scores also favored the active doses at later assessments through day 57. That’s promising after a single administration. But “durable” is a relative word here. Eight weeks of follow-up cannot tell us whether someone will feel better in six months, whether a second treatment is needed, or who might relapse.
About that two-hour claim
It’s the finding most likely to make its way into a breathless social post: 85% of the 8-mg group and 78% of the 12-mg group met discharge-readiness criteria within two hours.
Notice the word readiness.
The team began checking participants against predetermined discharge criteria 90 minutes after dosing. But the protocol did not actually allow anyone to leave before four hours had passed. So this was not a trial of clinics sending people home after a two-hour appointment.
What the result does suggest is that the acute drug effects may subside quickly enough to make shorter monitoring arrangements worth investigating. Compared with the long psychedelic sessions associated with substances such as psilocybin or LSD, that could eventually change the logistics of providing care.
Could it lower costs? Maybe. Could it let more patients access treatment? Possibly. But this study didn’t measure real-world staffing costs, insurance coverage, or the safety of a shorter release protocol. Before anyone starts selling the convenience angle, those questions need proper answers.
More intensity didn’t guarantee more benefit
There’s a longstanding tendency in psychedelic culture to treat a more overwhelming experience as a more transformative one. The results here complicate that assumption.
The lower active dose appeared to deliver similar antidepressant benefit, with a tolerability profile the authors considered more favorable. And researchers did not find evidence that scores on a questionnaire measuring mystical-type experiences correlated with improvement in depression at day 29.
That doesn’t mean the experience itself is irrelevant. A questionnaire can’t capture everything a person feels, and no single trial can settle how drug action, personal expectations, and psychological support interact. It simply means we shouldn’t assume that the intensity of a trip is a reliable measure of therapeutic success.
It’s one reason the researchers identified 8 mg as a dose to evaluate further. That’s a decision about the balance of results and tolerability in this study, not a recommended dose for the general public.
And the risks?
They’re part of the story, not a footnote.
Treatment-emergent adverse events were reported by 76% of people in the 8-mg group, 85% in the 12-mg group, and 73% in the low-dose group. Nearly all recorded events were classified as mild or moderate, and common complaints included nausea, headache, and discomfort at the administration site. Heart rate and blood pressure rose temporarily in some participants.
One participant receiving 12 mg experienced severe panic-attack events considered related to the treatment. It’s worth remembering that “generally well tolerated” in a research paper describes a particular sample under supervision. It isn’t a blanket safety guarantee.
People were screened, monitored, and supported. Some stopped taking antidepressants under medical supervision before dosing. The trial was too small to reliably detect rare harms, and its participants don’t represent everyone who might eventually seek treatment. Nor should anyone interpret these findings as an invitation to stop prescribed medication or experiment with 5-MeO-DMT outside clinical care.
We covered a separate 2026 study on self-reported adverse experiences with psychedelics recently. It asks a different question, and the two studies shouldn’t be combined as if uncontrolled use and a supervised clinical trial were the same thing.
The uncomfortable issue with psychedelic trials
“Double-blind” sounds wonderfully reassuring. In theory, neither participants nor the people evaluating treatment know who received which dose. In practice, that’s hard to maintain when one group experiences a powerful alteration of consciousness and another doesn’t.
In this trial, participants and on-site clinicians were often able to guess which treatment was given. Independent raters evaluating depression symptoms were better shielded from that information, which helps, but doesn’t make expectation effects disappear.
Other limitations matter too. The 8-mg group was comparatively small. Participants were not especially ethnically diverse. Some had to discontinue antidepressants, which can complicate how results apply in everyday medicine. And the study included psychological support without testing its contribution separately from the medication.
The research was funded by Beckley Psytech, an AtaiBeckley company associated with developing the formulation. Industry backing doesn’t make results false. It does make independent replication and transparent follow-up particularly important.
What happens next
The next meaningful test is larger phase 3 research. Researchers need to see whether the improvement survives stricter comparisons, whether the apparent benefits last, how rare or delayed harms emerge, and whether a clinical program built around a shorter experience is actually practical.
It’s easy to be cynical about psychedelic medicine’s promises. It’s just as easy to get swept up in them. Neither reaction does the research much justice.
What this trial offers is more specific, and more useful: evidence that a single, medically supervised dose of a short-acting psychedelic formulation improved depression ratings for some people with treatment-resistant illness over the following weeks. It also reveals how much work remains between a positive clinical trial and a treatment people can reliably access.
Maybe the long psychedelic session won’t be the only model. That’s an important possibility. Just don’t confuse a patient being ready to leave at two hours with a treatment that’s already ready for the world.
Sources and further reading
- Feifel D, Seynaeve M, Cubała WJ, et al. Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression. JAMA. Published October 26, 2026.
- JAMA: Research summary and study limitations
- ClinicalTrials.gov trial registration: NCT05870540
Editorial note: This is an evidence-based report on a clinical study, not medical advice. 5-MeO-DMT remains an investigational treatment in this context. Don’t use this article to guide self-medication or changes to prescribed treatment.